Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334108 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
A Phase 1 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05334108 is a Phase 1 study that has completed, run by Emalex Biosciences. The registered enrollment target is 56 participants.
The verdict
NCT05334108, a Phase 1 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
Interventions
- DRUG Ecopipam
- COMBINATION_PRODUCT Cohort 1 Probe Substrate Cocktail
- DRUG Cohort 2 Probe Substrate
- COMBINATION_PRODUCT Cohort 3 Probe Substrate Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05334108
The ClinicalTrials.gov registry entry for NCT05334108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ecopipam is the first listed.
NCT05334108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05334108 about?
NCT05334108 is a clinical study titled "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport". This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
What is the current status of trial NCT05334108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-04-26. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT05334108?
The interventions under investigation include: Ecopipam (DRUG), Cohort 1 Probe Substrate Cocktail (COMBINATION_PRODUCT), Cohort 2 Probe Substrate (DRUG), Cohort 3 Probe Substrate Cocktail (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05334108?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.